Edgewise Therapeutics Inc [EWTX] stock prices are down -1.59% to $27.85 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EWTX shares have gain 6.05% over the last week, with a monthly amount drifted -7.10%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Edgewise Therapeutics Inc [NASDAQ: EWTX] stock has seen the most recent analyst activity on January 22, 2025, when Stifel initiated its Hold rating and assigned the stock a price target of $30. Previously, Evercore ISI started tracking the stock with Outperform rating on November 22, 2024, and set its price target to $45. On March 07, 2024, Piper Sandler initiated with a Overweight rating and assigned a price target of $48 on the stock. Truist started tracking the stock assigning a Buy rating. Goldman downgraded its rating to a Sell but $5 remained the price target by the analyst firm on August 25, 2022. RBC Capital Mkts started tracking with a Outperform rating for this stock on April 13, 2022, and assigned it a price target of $31. In a note dated January 28, 2022, Goldman initiated an Neutral rating and provided a target price of $11 on this stock.
The stock price of Edgewise Therapeutics Inc [EWTX] has been fluctuating between $14.90 and $38.12 over the past year. Currently, Wall Street analysts expect the stock to reach $46.25 within the next 12 months. Edgewise Therapeutics Inc [NASDAQ: EWTX] shares were valued at $27.85 at the most recent close of the market. An investor can expect a potential return of 66.07% based on the average EWTX price forecast.
Analyzing the EWTX fundamentals
Gross Profit Margin for this corporation currently stands at 0.29% with Operating Profit Margin at -65.34%, Pretax Profit Margin comes in at -55.19%, and Net Profit Margin reading is -55.19%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.27 and Total Capital is -0.3. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 27.04 points at the first support level, and at 26.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 29.03, and for the 2nd resistance point, it is at 30.21.
Ratios To Look Out For
It’s worth pointing out that Edgewise Therapeutics Inc [NASDAQ:EWTX]’s Current Ratio is 26.35. Further, the Quick Ratio stands at 26.35, while the Cash Ratio is 2.36.
Transactions by insiders
Recent insider trading involved Russell Alan J, Chief Scientific Officer, that happened on Dec 30 ’24 when 100000.0 shares were sold. Director, ALAN J RUSSELL completed a deal on Dec 30 ’24 to buy 100000.0 shares. Meanwhile, Chief Development Officer Semigran Marc sold 29709.0 shares on Dec 24 ’24.
